Saudi Arabia Diabetes Market

The Saudi Arabia’s diabetes market size was valued at USD 385.2 Million in 2025 and is projected to reach USD 503.2 Million by 2034, exhibiting a CAGR of 2.92% during the forecast period 2026-2034. Rising prevalence of type-2 diabetes, growing obesity rates, strong Vision 2030 healthcare investment, and accelerating smart-therapy adoption are driving Saudi Arabia’s diabetes market growth. Insulin therapies lead at 58.6% share in 2025, while retail pharmacies account for 47.2% of national dispensing volumes.

Market Snapshot

The Saudi diabetes market growth trajectory from 2020 through 2034 demonstrates a steady expansion powered by chronic disease burden, expanding insurance coverage, and the rapid scale-up of specialty pharmacy channels across the Kingdom.

To get more information on this market, Request Sample

Sub-segment CAGR comparisons highlight e-commerce and tele-pharmacy as the fastest-growing distribution channel through 2034, while oral antidiabetics outpace insulin on a growth-rate basis.

The Saudi Arabia’s diabetes market is undergoing significant transformation, driven by a diabetes prevalence of nearly 18.7% among Saudi adults in 2025, a national obesity rate exceeding 24%, and accelerating digital health adoption. Valued at USD 385.2 Million in 2025, the market is forecast to reach USD 503.2 Million by 2034 at a CAGR of 2.92%.

Insulin therapies command a 58.6% share in 2025, driven by a large type-1 patient base and advanced type-2 cases requiring basal-bolus regimens. Oral antidiabetics represent 41.4% of global demand, growing faster on GLP-1 and SGLT-2 momentum. Retail pharmacies account for 47.2% of dispensing, supported by over 9,400 licensed outlets and rapid chain expansion.

Key Market Insights

Key Analytical Observations Supporting the Above Data:

• Insulin's 58.6% dominance in 2025 reflects a high burden of type-1 diabetes and advanced type-2 cases requiring basal-bolus regimens, with long-acting analogs commanding 42% of insulin revenues.
• Oral antidiabetics' 41.4% share is driven by expanding type-2 diagnoses and strong uptake of SGLT-2 inhibitors. GLP-1 prescription volume increased from 0.7 million in 2020 to 4.7 million by 2025, accounting for over 50% of diabetes prescriptions
• Retail pharmacies' 47.2% lead is underpinned by 9,000+ licensed outlets nationwide. Nahdi Medical alone operates over 1,150 pharmacies, reinforcing its position as the largest organized pharmacy chain and a key driver of prescription refill volumes.
• E-Commerce's 21.7% share is expanding at year-on-year, supported by Nahdi Online, Al Dawaa digital services, and third-party aggregators integrated with the Seha platform.
• Smart insulin and CGM demand reached 22% of insulin-treated patients in 2025, driven by Ministry of Health pilot programs, private insurance coverage expansion, and payer-funded outcomes programs.

Diabetes therapies in Saudi Arabia span insulin formulations, oral antidiabetics, GLP-1 receptor agonists, and adjunct medical devices. The market includes a broad portfolio of rapid-acting analogs, long-acting basal insulins, combination therapies, and smart delivery devices - catering to a diverse patient base ranging from newly diagnosed type-2 cases to complex type-1 management.

The industry operates at the convergence of rising chronic disease burden, Vision 2030 health reforms, evolving reimbursement frameworks, and smart-home health integration. Growth is underpinned by strong government investment, with Saudi Arabia allocating SAR 259 billion (USD ~69 billion) to healthcare and social development in the 2026 budget, alongside rising healthcare expenditure of ~SAR 200 billion and plans to expand infrastructure through the construction of 20+ new hospitals, reinforcing long-term capacity expansion, and increasingly stringent quality standards under SFDA oversight. The market is undergoing a structural shift toward connected, personalized, and technology-enabled diabetes care.

To evaluate market opportunities, Request Sample

Market Drivers

• Rising Disease Prevalence: Saudi Arabia has over 5 million adults living with diabetes, with the patient base continuing to expand annually in line with rising prevalence trends.
• Vision 2030 Healthcare Investment: The Kingdom allocated SAR 259 billion to healthcare modernization through 2030. Programs such as the Health Sector Transformation and health clusters directly uplift chronic disease management, boosting formulary depth for diabetes therapies.
• Obesity Epidemic: National obesity rates surpassed 23% among adults in 2024. This structurally elevates type-2 diabetes incidence and long-term therapy demand, accelerating adoption of GLP-1 receptor agonists and combination oral antidiabetics.
• National Screening Expansion: Diabetes screening programs in Saudi Arabia have expanded significantly through national initiatives, with large-scale campaigns screening hundreds of thousands of individuals and broader population-wide programs targeting millions of at-risk adults annually.

Market Restraints

• Therapy Affordability: Average out-of-pocket cost for insulin-based therapy reached SAR 300 per month in 2025 for uninsured households. This cost burden constrains adoption among lower-income and expatriate demographics lacking private coverage.
• Adherence Gap: Diagnosed patients discontinued therapy within 12 months. Poor long-term adherence limits per-patient revenue capture and elevates complication-related costs across the health system.
• Import Dependency: Most finished dosage forms were imported in 2025, exposing the market to foreign exchange volatility and supply chain disruption - a factor that strains price stability for branded and generic therapies alike.

Market Opportunities

• CGM Penetration Expansion: Continuous glucose monitoring adoption remains in early stages but is expected to expand significantly over the next 3–5 years as awareness, affordability, and reimbursement improve. This unlocks a multi-billion-riyal device and data services opportunity, especially for insulin-treated patients.
• Local Manufacturing Localization: Under Vision 2030 and ‘Made in Saudi’ initiatives, the Kingdom is accelerating pharmaceutical localization, with domestic manufacturing currently covering ~36% of demand across 40+ factories and targeted to expand significantly through policy incentives and investment support—creating strong capacity expansion opportunities for local players such as SPIMACO, Tabuk Pharma, and Jamjoom Pharma.
• Digital Therapeutics Growth: Digital therapeutics adoption in Saudi Arabia is supported by strong patient receptivity, with 55–62% of users expressing willingness or comfort in using digital health solutions, based on national survey data.

Market Challenges

• Specialist Shortage: Specialist availability in Saudi Arabia remains uneven, with endocrinology services concentrated in major urban centers such as Riyadh and Jeddah, while peripheral regions face limited access to specialist care, constraining the adoption of complex diabetes management and advanced device-based therapies.
• Complication Burden: Diabetes-related complications - nephropathy, retinopathy, and neuropathy .Rising complication rates elevate total cost of care and strain payer budgets.
• Regulatory Approval Timelines: Average SFDA approval timeline for novel biologics reached 14 months in 2024. This lag delays access to next-generation incretin therapies and premium insulin analogs relative to global launch markets.

1. Smart Insulin Delivery and Connected Pens

Smart insulin pens with Bluetooth-enabled dose tracking are gaining traction in unit sales. These devices integrate with digital health platforms such as the Seha app and third-party systems to improve adherence, reduce hypoglycemia risk, and enable remote titration for type-1 and advanced type-2 diabetes patients.

2. Continuous Glucose Monitoring (CGM) Adoption

Adoption of continuous glucose monitoring (CGM) in Saudi Arabia remains at an early but rapidly expanding stage, with usage still limited due to cost and access barriers but increasing steadily alongside market growth. Clinical studies demonstrate meaningful improvements in glycemic control, with HbA1c reductions ranging from ~0.3% to over 1% depending on patient cohorts, while device accuracy aligns with global benchmarks, with mean absolute relative difference (MARD) typically below 9%.

3. Digital Therapeutics and Remote Care

Multiple digital diabetes programs were piloted across Saudi Arabia’s tertiary hospitals, with strong engagement levels indicating durable behavior change, particularly for lifestyle-driven type-2 diabetes and pre-diabetes progression risk management.

4. AI-Enabled Clinical Decision Support

AI-based risk stratification tools have been deployed across multiple tertiary hospitals, with early adopters reporting meaningful reductions in diabetes-related emergency admissions and improved efficiency in insulin titration workflows compared to manual approaches.

5. Closed-Loop Insulin Delivery Systems

Closed-loop systems, often referred to as artificial pancreas devices, have begun limited commercial launches, with adoption expected to expand among type-1 diabetes patients in Saudi Arabia, potentially reshaping traditional basal-bolus treatment economics.

The Saudi Arabia’s diabetes value chain spans six integrated stages from upstream API supply through patient-facing dispensing. Each stage presents distinct competitive dynamics, margin profiles, and technology investment requirements relevant to the overall Saudi Arabia’s diabetes market analysis.

OEM pharma manufacturers hold the highest strategic value by integrating APIs, device components, and technology into turnkey therapy platforms. Meanwhile, e-commerce and tele-pharmacy channels are reshaping distribution, letting manufacturers bypass intermediaries, strengthen patient relationships, and capture higher margins.

Advanced Insulin Analogs and Biologics

Long-acting basal analogs such as insulin degludec and glargine U300 dominate the analog insulin category. GLP-1 receptor agonists represented one of the fastest-growing classes in 2025, with prescription volumes up ~34% year-on-year. Dual GIP/GLP-1 agonists also entered the Saudi market in 2024, expanding therapy options for obesity-diabetes crossover patients.

Device and Materials Innovation

Ultra-thin pen needles, microneedle patches, and biocompatible polymer sensors are gaining traction, with local trials of continuous glucose monitoring systems demonstrating accuracy comparable to global benchmarks, as reflected in low mean absolute relative difference (MARD). Advances in stainless steel and medical-grade polymers are underpinning the shift toward more durable, user-friendly drug delivery devices.

Smart Connectivity and IoT Integration

Adoption of connected diabetes devices is increasing, with Bluetooth-enabled insulin pens and digital health platforms enabling real-time data tracking and integration with telemedicine apps such as Seha and national electronic health record systems, improving visibility and continuity of care. Wi-Fi- and Bluetooth-enabled devices are transitioning from niche offerings to mainstream diabetes-care essentials.

Automation and Clinical AI

Automated insulin titration algorithms have demonstrated clinical benefits, with randomized controlled trials showing ~0.4% reductions in HbA1c and systematic reviews indicating improved glycemic control and faster achievement of glucose targets.

IMARC Group provides an analysis of the key trends in each segment of the Saudi diabetes market, along with forecasts at the national and regional levels from 2026 to 2034. The market has been categorized based on segment and distribution channel as per the quantitative data available.

By Segment

To access detailed market analysis, Request Sample

Insulin leads the Saudi Arabia’s diabetes market with a 58.6% share in 2025. Demand is driven by a large type-1 patient base and advanced type-2 cases requiring basal-bolus regimens. The Saudi insulin sub-segment was valued at approximately USD 225.7 Million in 2025 and is projected to grow at a 2.6% CAGR through 2030. Long-acting analog insulins account for ~42% of insulin revenues, reflecting preference for once-daily dosing and lower hypoglycemia risk.

Oral antidiabetics account for 41.4% of market revenues in 2025, worth approximately USD 159.5 Million. Demand is driven by expanding type-2 diagnoses and strong uptake of SGLT-2 inhibitors. GLP-1 receptor agonist prescriptions rose ~34% in 2025 as obesity-linked demand surged. Consumer preference for once-weekly dosing and dual GIP/GLP-1 agonists is expanding average selling prices across this class.

By Distribution Channel

Retail pharmacies dominate the distribution landscape with a 47.2% share in 2025. Nahdi Medical operate around 983 outlets combined, capturing a disproportionate share of refill volumes. Private insurance reimbursement through Bupa Arabia, Tawuniya, and MedGulf supports volume growth.

Hospital pharmacies represent 31.1% of dispensing volumes in 2025, worth around USD 119.8 Million. These outlets are central to first-fill insulin initiation and complex therapy management, anchored by MoH facilities and private networks such as Saudi German Hospitals, HMG, and Sulaiman Al Habib. E-commerce and tele-pharmacy reached 21.7% share, translating to roughly USD 83.6 Million, with ~26% year-on-year growth supported by Nahdi Online, Al Dawaa digital services, and third-party aggregators integrated with Seha.

Competitive Landscape

The Saudi Arabia diabetes market's competitive landscape is moderately consolidated, with global innovators competing alongside fast-growing local manufacturers. Leading players compete on product innovation, IoT integration, adherence programs, SFDA compliance, and sustainability credentials. Strategic partnerships and localization commitments are key tools - Sanofi signed a localization MoU in 2025, while Eli Lilly introduced Mounjaro with ~48% YoY prescription growth through end of 2025.

Novo Nordisk

Novo Nordisk is the global leader in insulin and GLP-1 therapies, headquartered in Bagsværd, Denmark. Founded in 1923, it operates through Novo Nordisk Saudi Arabia with a local commercial and medical affairs team and serves the market through NUPCO tenders and private-sector distribution.

• Product & Platform Portfolio: Novo Nordisk's Saudi portfolio spans NovoRapid, Levemir, Tresiba, Ozempic, Victoza, and Xultophy - covering rapid-acting, long-acting, and GLP-1 classes with adherence-supporting smart pen accessories.
• Recent Developments: In April 2025, Novo Nordisk signed a localization agreement with Lifera, a Saudi biotech platform, to manufacture GLP-1 therapies locally, including semaglutide-based treatments such as Ozempic and Wegovy, supporting Saudi Arabia’s National Biotech Strategy and domestic production goals.
• Strategic Focus: Novo Nordisk's strategy centers on premium innovation, obesity-diabetes crossover therapies, and digital adherence tools aligned with Saudi Vision 2030 health cluster priorities and growing private insurance coverage.

Sanofi

Sanofi is a French multinational with a strong diabetes and cardiovascular franchise. It operates Sanofi Arabia with Riyadh headquarters and regional distribution across the MENA region. The company has participated in Saudi diabetes care for over three decades.

• Product & Platform Portfolio: Sanofi's portfolio includes Lantus, Toujeo, Apidra, Soliqua, and Admelog - covering basal, rapid, and fixed-ratio combination therapies aligned with updated Saudi clinical guidelines.
• Recent Developments: In 2024, Sanofi launched Toujeo Max SoloStar in the Saudi market. In 2025, the company signed a localization MoU with a Saudi manufacturer and expanded its SFDA-approved biosimilar pipeline.
• Strategic Focus: Sanofi's focus is on portfolio consolidation around long-acting analogs and fixed-ratio combinations, deeper MoH tender participation, and strategic localization under Made in Saudi incentives.

Eli Lilly and Company

Eli Lilly is a US-based innovator with leading GLP-1 and dual agonist assets. Saudi operations are supported by a regional office and local distributor partnerships. The company has significantly increased Saudi commercial investment since 2022.

• Product & Platform Portfolio: Eli Lilly's Saudi portfolio includes Humalog, Humulin, Trulicity, Mounjaro, and co-promoted Jardiance. Mounjaro is a flagship growth driver for obesity-diabetes crossover care.
• Recent Developments: Awareness and interest in Mounjaro have increased significantly in Saudi Arabia, with ~93% of surveyed individuals familiar with the therapy and ~92% perceiving it as effective for weight loss, although knowledge gaps persist and only ~50% have consulted physicians—highlighting growing demand alongside the need for structured clinical guidance.
• Strategic Focus: Eli Lilly's strategy focuses on aggressive expansion of GIP/GLP-1 dual agonists, targeted obesity-diabetes clinical programs, and deeper commercial coverage in Riyadh, Makkah, and the Eastern Province.

The Saudi Arabia’s diabetes market exhibits moderate concentration. The top five players - Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, and Merck - collectively account for approximately 61% of global market revenue in 2025. Novo Nordisk alone holds an estimated 22.4% share, reflecting its deep insulin franchise and growing GLP-1 footprint.

The market is experiencing a bifurcated dynamic. At the premium OEM tier, consolidation is occurring around brand equity, IoT platform capabilities, and clinical evidence depth. Simultaneously, Saudi domestic manufacturers are generating competitive challenges through cost-competitive generics and biosimilars targeting tender volume. This dual dynamic is intensifying competition across all price tiers through 2034.

The Herfindahl-Hirschman Index is estimated below 2500 for 2025, sitting just below the high-concentration threshold. The long tail of over 30 local and regional manufacturers ensures healthy competitive dynamics, with at least two anticipated M&A transactions expected in the Saudi diabetes space over the next 36 months.

Fastest-Growing Segments

Saudi Arabia’s e-pharmacy market was valued at USD 923.6 million in 2024 and is projected to reach USD 2.1 billion by 2030, growing at a CAGR of ~14.7%, driven by rising internet penetration, increasing digital health adoption, and growing demand for convenient access to medications.

Emerging Sub-Market Opportunities

Pediatric Type 1 diabetes represents a significant burden in Saudi Arabia, with 35,000 children and adolescents (0–19 years) affected, according to International Diabetes Federation estimates, highlighting a large but underpenetrated population for advanced insulin delivery and CGM technologies.

Venture and Strategic Investment Trends

Saudi Arabia’s healthtech market is projected to grow from ~USD 2.93 billion in 2024 to ~USD 14.43 billion by 2033, at a CAGR of 19.4%, driven by rapid digital adoption, telehealth expansion, and rising demand for chronic disease management solutions—particularly in diabetes, which accounts for over 30% of the market.

The Saudi Arabia’s diabetes market forecast projects steady value expansion from USD 385.2 Million in 2025 to USD 503.2 Million by 2034 at a CAGR of 2.92%.

Three key shifts will reshape the Saudi diabetes market through 2034. First, smart-home and CGM convergence will embed diabetes management into integrated care pathways, making connected fixtures standard in new patient initiations by 2028-2030. Second, localization and biosimilar scale-up will shift domestic manufacturing share from ~18% in 2025 to nearly 28% by 2034. Third, AI-enabled titration and closed-loop insulin delivery are expected to transform complex-patient economics, reaching ~12% of type-1 patients by 2034.

Primary Research

Primary research encompassed structured interviews conducted in 2024-2025 with 42 Saudi diabetes industry stakeholders, including endocrinologists, hospital pharmacy directors, retail chain category managers, NUPCO tender specialists, and multinational commercial heads. Primary insights validated market sizing, segmentation estimates, regional splits, and technology adoption timelines.

Secondary Research

Secondary sources include SFDA filings, Ministry of Health statistics, International Diabetes Federation (IDF) atlas editions, NUPCO tender disclosures, IQVIA Saudi retail audits, and annual reports of listed Saudi pharmacy chains such as Nahdi Medical and Al Dawaa. Regulatory updates from SFDA and public statements from Vision 2030 health cluster leadership were also incorporated.

Forecasting Models

Market size estimations and growth projections were derived using a combination of bottom-up forecasting by drug class and distribution channel, cross-validated with top-down macro drivers such as diabetes prevalence, diagnosis rates, and per-capita health spending. Scenario analysis (base, optimistic, and conservative cases) was performed with CAGR sensitivity of +/- 80 basis points to account for macroeconomic and regulatory uncertainty.

Saudi Arabia Diabetes Market Report Coverage: